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Abstract
American trypanosomiasis, commonly known as Chagas disease, is caused by the flagellate protozoan parasite
Trypanosoma cruzi. An estimated eight million people infected with T. cruzi currently reside in the endemic
regions of Latin America. However, as the disease has now been imported into many non-endemic countries
outside of Latin America, it has become a global health issue. We reviewed the transmission patterns and
current status of disease spread pertaining to American trypanosomiasis at the global level, as well as recent
advances in research. Based on an analysis of the gaps in American trypanosomiasis control, we put forward
future research priorities that must be implemented to stop the global spread of the disease.
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Introduction
American trypanosomiasis, commonly known as
Chagas disease, is caused by the hemoflagellate proto-
zoan parasite Trypanosoma cruzi. It has been a
neglected tropical disease and an important health
problem in Latin America for many decades. With no
vaccine yet available, only two proven drugs, namely
benznidazole and nifurtimox, can be used for efficient
treatment of acute cases. However 95 % of untreated
patients advance into the chronic stage of the disease;
at least 30 % then develop chagasic cardiomyopathy
and up to 10 % can develop digestive, neurological,
or mixed alterations. These all can lead to high mor-
bidity and mortality rates among adults in endemic
countries; the current number of annual deaths is at
least 10,000 [1]. Chagas disease has been estimated to
cost approximately 667,000 disability-adjusted life
years [2]. The World Bank and World Health
Organization (WHO) consider Chagas disease as the
fourth most important infectious disease after malaria,
tuberculosis, and schistosomiasis [3].
The disease is estimated to affect around eight million
people in the Western Hemisphere, who are mainly dis-
tributed in Latin America. At least 120 million people
are at risk of contracting the disease [1]. The highest
prevalence of Chagas disease has been reported in
Bolivia (6.75–15.4 %), followed by Paraguay (0.69–9.3 %)
and Panama (0.01–9.02 %) [4, 5] (see Table 1). However,
the total number of cases in Brazil (0.8–1.30 %), Mexico
(0.5–6.8 %), and Argentina (4.13–8.2 %) together ac-
count for almost 60 % of all people infected with T. cruzi
in Latin America [4, 5]. In the last decade, due to in-
creasing levels of migration, important epidemiological
changes have occurred and the disease has now spread
to non-endemic countries. Geospatial data from 2002 to
2011 demonstrated that Chagas disease has existed in
countries outside of Latin America (see Fig. 1). For in-
stance, Chagas disease has been diagnosed in non-
endemic countries in North America, such as Canada
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Region, such as Australia and Japan; as well as in Europe
[6–9]. Transmission of Chagas disease has now become
a global health issue and has attracted much more atten-
tion than ever before [10]. In this review, we outline the
research priorities needed to stop the current spreading
pattern of the disease based on a gap analysis of needs
in the epidemiology and control of American
trypanosomiasis.
Review
Patterns of American trypanosomiasis transmission
In endemic areas, the most common way T. cruzi infec-
tions occur are through vector-borne transmission by
triatomine insects, followed by blood transfusions [11].
Triatomine bugs, especially Triatoma infestans and
Rhodnius prolixus, are considered to be the most im-
portant two vectors of T. cruzi. In non-endemic areas,
Table 1 Burden of Chagas disease and screening of blood donors for T. cruzi in Latin America
Country Estimated T. cruzi
prevalence (%) [5]
Transmission by principal




blood donor (%) [29, 75]
Argentina 4.13–8.20 Not interrupteda 100 4.50
Belize 0.74 Interrupted 100 0.40
Bolivia 6.75–15.40 Not interrupted 86 9.90
Brazil 0.80–1.30 Not interrupteda 100 0.61
Chile 0.99–2.80 Interrupted (1999) 75b 0.47
Colombia 0.48–1.20 Not interrupted 99 2.80
Costa Rica 0.53–11.70 Interrupted 99 0.98
Ecuador 0.20–1.74 Not interrupted 100 0.15
El Salvador 3.37–6.10 Interrupted (2010) 100 2.46
Guatemala 1.98–7.89 Interrupted (2009) 100 0.79
Honduras 3.05–5.80 Interrupted (2011) 100 1.40
Mexico 0.50–6.80 Not interrupteda 100c 1.50
Nicaragua 1.14–1.70 Interrupted (2011) 100 0.49
Panama 0.01–9.02 Not interrupted 98 0.90
Paraguay 0.69–9.30 Not interrupteda 99 2.80
Peru 0.20–3.00 Not interrupteda 99 0.26
Uruguay 0.60–1.20 Interrupted (1997) 100 0.47
Venezuela 1.16–4.00 Not interrupted 100 0.67
aThe principal vector has been eliminated in some provinces and transmission by the principal vector has been interrupted in some provinces
b98 % in endemic regions
cScreening for 18 government-run transfusion centers
Fig. 1 Mapping data showing epidemiological changes pertaining to Chagas disease between 2002 and 2011 (red refers to endemic areas where
transmission is through vectors; yellow refers to endemic areas where transmission is occasionally through vectors; blue refers to non-endemic
areas where transmission is through blood transfusion or organ transplantation, etc.)
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where no vectors exist, other transmission routes, such
as blood transfusions, organ transplantation, or congeni-
tal transmission, are predominant.
Transmission routes of Chagas disease are generally
divided into two streams, based on the frequency of
transmission and epidemiological importance. Firstly,
the most common routes for T. cruzi transmission in-
clude vector transmission, oral transmission, transfusion,
and vertical or congenital transmission [12]. In the
vector transmission mode, T. cruzi is transmitted by
blood-sucking bugs of the family Reduviidae, subfamily
Triatominae. This transmission route has the largest im-
pact in Latin American countries and is also responsible
for maintaining the pathogen life cycle of the disease. In
this case, the parasite develops in the body of the insect
vector after it has fed on the blood of an infected host.
The infective form of the parasite is then transmitted to
humans via the excreta of the triatomine insect through
mucous membranes or breaks in the skin. Parasites then
enter the bloodstream and invade cells of the monopha-
gocytic system. The life cycle of T. cruzi transmitted
through triatomine insects is shown in Fig. 2. Although
more than 140 different species of triatomines have been
identified, only a relatively small number are significant
vectors. Fourteen species are the main vectors in the syl-
vatic and domestic cycle, namely Triatoma infestans, T.
sordida, T. pseudomaculata, T. tibiamaculata, T. arthur-
neivai, T. brasiliensis, T. dimidiata, Panstrongylus megis-
tus, P. geniculatus, P. diasi, Rhodnius neglectus, R.
prolixus, R. megistus, and R. domesticus [9]. However,
the main species related to T. cruzi transmission vary ac-
cording to different regions and settings. For instance, T.
infestans is more dominant in Southern Cone countries,
whereas R. prolixus is closely associated with palm trees
and maintains enzootic T. cruzi cycles in Central
America [3, 9]. Triatomines can be of both sexes and
have five nymphal stages, all of which are involved in
the transmission of T. cruzi [3]. Furthermore, T. cruzi
can be orally transmitted by ingestion of contami-
nated food or liquid. Several outbreaks of oral Chagas
disease have been reported in Brazil, Colombia, and
Venezuela, with acute cases arising after patients ate
food contaminated with vector feces and urine [13, 14].
The largest worldwide outbreak of oral Chagas disease oc-
curred in Venezuela in 2007, with a total of 103 acute
cases, 80 % of those being children [13].
T. cruzi can also be transmitted to humans via non-
vector mechanisms including blood transfusion and con-
genital transmission, which are the main causes of infection
in urban areas and non-endemic countries. For instance, in
Brazil alone, in the 1970s, it has been estimated that
100,000 new Chagas disease cases annually occurred due to
blood transfusions [9]. A total of 885,187 blood samples
collected in El Salvador between 2001 and 2011 revealed
21,693 cases of transfusion-related infections [15]. There is
also evidence of the disease occurring due to blood transfu-
sions in non-endemic countries. Up until 2013, at least
eight cases of blood transfusion-related infections were
Fig. 2 Life cycle of the T. cruzi parasite in triatomine insects and humans
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reported in Canada and the US [16]. Congenital or vertical
transmission occurs when infected mothers transmit the
parasite, which can cross the placental barrier to their off-
spring during the gestation period [17]. Up until 2014,
eleven cases of congenital Chagas disease have been re-
ported in Japan and Europe [18]. A systematic literature
review revealed that the estimated global rate of T. cruzi
congenital transmission was 4.7 %- 5.0 % in endemic coun-
tries and 2.7 % in non-endemic countries [19, 20]. The
number of annual cases of congenital Chagas disease has
been estimated at 14,385 in Latin America, 66–638 in the
US, and 20–183 in Europe [17].
Secondly, there are more uncommon or accidental
modes of transmission. These include organ transplant-
ation routes, ingestion of maternal milk contaminated
with the protozoan parasites, and laboratory accidents
[12]. Several cases of transmission via organ transplants
have been reported recently as a novel transmission
mode of Chagas disease [21, 22]. In the US, it was esti-
mated that approximately 300 patients annually may
have acquired Chagas disease through transplants [23].
Furthermore, T. cruzi can be orally transmitted by inges-
tion of contaminated maternal milk. Transmission of
Chagas disease from mother to child through contami-
nated breast milk was first described by Mazza et al. in
1936, but since then, transmission through breastfeeding
in humans has not been reported again [17]. Because of
this, most scientists and doctors still recommend that
breastfeeding is the ideal way of providing nutrition dur-
ing the first six months of life by mothers with chronic
Chagas disease [20, 24]. More rarely,T. cruzi can be trans-
mitted to people who work with cultured parasites [25].
Advances in the control of American trypanosomiasis
Various studies on the interruption of transmission of
American trypanosomiasis have been conducted in Latin
American countries since the last century, and the
progress of these initiatives has been widely reviewed
[26, 27]. Since July 1991, multinational initiatives
against Chagas disease have been launched in the
Southern Cone by the Ministries of Health of
Argentina, Bolivia, Brazil, Chile, Paraguay, and
Uruguay. In 1997, the initiatives of the Andean Countries,
and of Central America and Mexico have been created.
All the initiatives have the same or similar aims, which
were to (i) interrupt the transmission of Chagas disease by
eliminating domestic vectors, (ii) screen blood donors to
reduce the risk of transfusion transmission, and (iii) pro-
mote maternal screening for infection, followed by treat-
ment of infected newborns where necessary [28, 29]. All
endemic countries have joined the multinational initiatives
against Chagas disease, namely surveillance and control of
the disease and its vectors, at the beginning of this cen-
tury. Several achievements were implicit to leading to the
control of the disease. First, the distribution of domestic
vectors has been markedly reduced, and although trans-
mission has not been completely interrupted, effective
control measures have been implemented over vast areas.
Transmission by principal domestic vectors has been ef-
fectively controlled in Uruguay (1997), Chile (1999), Brazil
(2006), El Salvador (2010), and substantial areas of
Argentina, Bolivia and parts of Central America (see
Table 1) [2, 29–31]. Effective vector control has also re-
duced the reinfection rate of the disease, which was con-
sidered a key factor for severe morbidity in earlier decades
[32, 33]. Second, extensive screening of blood donors for
T. cruzi infection has been carried out in most Latin
American countries, with the majority having a 100 %
coverage rate of blood-donor screening (see Table 1)
[2, 12]. It has been reported that the seroprevalence of
Chagas disease among blood donors has dropped from
7 to 0.6 % between 1970 and 2006 [12, 34]. The num-
ber of people who are infected with Chagas disease
has reduced from thirty million people in 1990 to
eight million people [1, 2]. This is based on the fact
that the new infection rate of Chagas disease has de-
clined to zero in substantial areas in Latin America
[2]. Third, congenital infection has been reduced as
the apparent rate of transplacental transmission from
chronically infected mothers has declined in areas
where vector transmission has been interrupted. Con-
sequently, the medical benefits of control initiatives
are reflected in the decline of new acute infections
and severity of chronic disease cases [29].
With the disease prevalence reduced significantly, a
new International Initiative for Chagas Disease Surveil-
lance and Prevention in the Amazon (AMCHA), spon-
sored by the European Community and the Latin
America Triatominae Network, was launched in 2002.
This programme has three main objectives, namely to (i)
evaluate the risks of Chagas disease in these regions and
propose monitoring and prevention of disease transmis-
sion, (ii) identify the research requirements for the mon-
itoring and prevention of Chagas disease and, (iii)
promote or establish an international cooperation sys-
tem for the disease [28]. To fulfill this goal, it has been
suggested that to best implement disease control, techni-
cians should be trained to recognize triatomines for epi-
demiology surveillance, in order to make clinical
diagnoses and provide treatment. Since then, a Techni-
cian Capacitation Manual for the detection of T. cruzi
has been created [28].
What needs to be done to control and eliminate
the transmission of American trypanosomiasis
In endemic regions
Although there have been many achievements related to
Chagas disease in endemic countries, controlling the
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disease still poses many challenges due to its zoonotic
nature, which involves different domestic and wild reser-
voirs. Some of the reasons why controlling the transmis-
sion of the disease is so difficult are: native vectors
reinfesting human habitats, modifications in population
dynamics, and the development of resistance to insecti-
cides. The other possible distracting element is that, in
some areas, another species of triatomine bugs has
adapted or substituted the principal vectors. For ex-
ample, T. dimidiata and R. ecuadoriensis may be feasible
candidates for elimination in Ecuador and northern
Peru, T. barberi may be a candidate for eradication in
Mexico, and T. pallidipennis may require a more long-
term control approach in Central America [32]. More
recently, the goal for the certification of the “control of
the vector transmission of T. cruzi” as an alternative to
the “interruption of the vector transmission of T. cruzi”
in endemic countries was proposed by the Southern
Cone Initiative to Control/Eliminate Chagas Disease
(INCOSUR) [35–37]. Thus, new fundamental concepts
have been implicated in the following ways. First is that
native vectors has not been eliminable, the entomo-
logical surveillance and response system must be sus-
tained, and operational interventions must be continued
to minimize infection risks. Second is that there is a
need to reestablish a regional evaluation mechanism for
the control of native species, as the existing framework
was developed on the basis of experiences of controlling
vectors and on the sustainability of those control efforts.
Some researchers have indicated that they prefer to sus-
tain the surveillance and response systems for native
vectors and to certify good practices that can improve
disease control [35, 37, 38]. The control of native vectors
of Chagas disease is an enduring challenge, and sub-
regional initiatives can greatly contribute to the coun-
tries’ efforts by providing result- and process-driven
evaluations.
To control Chagas disease, interruption of transfusion
transmission is a very important target in control pro-
grammes of endemic countries. Therefore, extensive
blood-donor screening for T. cruzi infection is the main
measure implemented in all of the endemic Latin
American countries, though the coverage has not yet
reached 100 % (see Table 1). After the implementation
of the transmission control programme, the rate of new
infections has markedly declined over large areas. How-
ever, despite this decline, a great challenge still remains.
The interruption is defined as seroprevalence being
zero among children aged between 0 and 15 years (op-
tionally the target age could be between 0 and 5 years)
[35]. Thus, the evaluation requires (i) seroprevalence
among children under 15 years of age as the principal
indicator, and (ii) geographic coverage of surveillance
on native vectors and acute cases [35]. Making the
interruption of transmission a regional goal would con-
tinue offering political incentives and provide the long-
term vision in Latin American countries. Meanwhile,
seroprevalence among women of childbearing age (15–44
years of age) has also become a focus because by inter-
rupting congenital or vertical transmission, infections
among young individuals can be reduced [39]. There is no
reliable method for preventing congenital infection. The
most effective strategy is widespread treatment of T.
cruzi-affected women of childbearing age with routine
serological screening, as well as prompt treatment of chil-
dren born to infected mothers. Information, education,
and communication programmes on Chagas disease and
its congenital transmission route still need to be strength-
ened at the community level [20].
Oral transmission of T. cruzi through infection by
bites of blood-sucking triatomine bugs has aroused at-
tention because of several outbreaks in Latin American
countries. This transmission mode is considered an
emerging threat because the outbreaks are sporadic, dif-
ficult to predict, characterized by high mortality rates,
and have shown no signs of declining in frequency or se-
verity [40]. Another challenge is high therapeutic failure,
which has been detected in these outbreaks, and data
suggest that genetic polymorphism exists in parasite
populations [11]. Therefore, the current aim to deal with
oral transmission of Chagas disease is focused on identi-
fying the pertinent risk factors, triatomine species in-
volved, and parasite polymorphisms. There is also a
need for ongoing epidemiological surveillance and con-
trol policies.
Therefore, in endemic countries, long-term regional
goals taking into consideration the available evaluation
systems to interrupt transmission via intradomiciliary
vectors and blood transfusions provide clear direction
and incentive to governments, scientific communities,
and donors alike.
In non-endemic regions
Globalization has led to some infectious diseases being
widely distributed around the world. Recent trends in
global migrations from rural to urban areas, and from
endemic to non-endemic countries, have increased the
threat of spreading Chagas disease at the global level.
For instance, it is estimated that there are more than 26
million Latin American immigrants living in Europe, the
US, Canada, Japan, and Australia, which increases the
risk of Chagas disease spreading to these non-endemic
countries (see Table 2). The first case of imported T.
cruzi infection was reported in Romania in 1981 [41].
Since then, an increasing number of cases has been re-
ported in Japan, the US, and Europe, which is due to the
migration of people from endemic areas [6, 16, 42, 43].
The US has the largest number of Latin American
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Table 2 Data on American trypanosomiasis spreading to non-endemic countries outside of Latin America*
Indicators Austria Belgium Croatia Denmark France Germany Italy Netherlands Portugal
Estimated number of Latin American immigrants 7552 38,133 ND ND 208,395 58,000 440,000 35,211 83,000
Estimated number of T. cruzi cases 140–180 1982 ND ND 2116 935 5,520–7,081 480 850
Number of laboratory confirmed cases 2 19 1 1 111 2 114 7 8
Estimated number of pregnant women with T. cruzi infection ND 16 ND ND ND ND 30 18 50
Estimated number of cases of congenitaltransmission ND 1 ND ND 19 ND 2 2 2
Number of patients treated + 2 3 ND ND 28 ND 22 ND ND
Serological screening of blood donors Yes No No No Yes No Yes No Yes
Presence of a systematic detection system for congenital
infection
No No No No No No Yesc No No
Presence of a systematic detection system for organ, tissue,
and cell donors of T. cruzi
No No No No Yes No Yes Yesa No
Indicators Romania Spain Sweden Switzerland UK Canada US Australia Japan
Estimated number of Latin American immigrants ND 2,090,695 58,196 60,000–90,000 400,000 100,000 22,000,000 116,430 371,700
Estimated number of T. cruzi cases ND 47,738–67,423 1,118 3,000 14,000 1,789 300,167 1,928 3,592
Number of laboratory confirmed cases 1 3,617 1 256 28 1 799 1 46
Estimated number of pregnant women with T. cruzi infection ND 914–1,656 ND 30 50 ND ND ND ND
Estimated number of cases of congenitaltransmission ND 41–121 1 5 5 ND ND ND ND
Number of patients treated + ND 195 1 99 0 ND ND ND ND
Serological screening of blood donors No Yes No Yes Yes No Yes No No
Presence of a systematic detection system for congenital
infection
No Yesc No Yesc Nob No No No No
Presence of a systematic detection system for organ, tissue,
and cell donors of T. cruzi
No Yes NO No Yes No No No No
* Data sourced from [29, 44–46, 49]
+ Treated with benznidazole or nifurtimox
ND Not determined
aOnly known Chagas disease patients are excluded from donating blood or organs, tissues, and cells for transplantation
bAdvocacy is carried out for screening of at-risk mothers














immigrants, estimated at 22 million, with T. cruzi infec-
tion cases estimated at around 300,167 [44]. In Europe,
the estimated total number of migrants from Latin
America is more than 3.5 million, with T. cruzi infection
cases estimated to be between 77,000 and 100,000 [45].
In Canada, Australia, and Japan, there are an estimated
total of 100,000, 116,430, and 371,700 Latin American
migrants, respectively, with T. cruzi infection cases es-
timated at around 1,789, 1,928, and 3,592, respectively
[30, 40, 46, 47] (see Table 2). Due to the absence of
vectors in non-endemic countries, prevention and
control measures of Chagas disease in such areas must
be different from those in endemic areas. The focus
should be placed on the risk of transmission through
blood transfusions; organ, tissue, or cell transplants;
and congenital transmission, as well as potentially ac-
quiring infection during travel to endemic areas.
Therefore, the following strategies for prevention of
the disease spreading to non-endemic countries are
needed.
First, more joint efforts should be made at the global
level to stop the disease spreading. Since 2007, the
WHO has conducted a series of meetings, including
“Control and prevention of Chagas disease in Europe
(2009)” and “Informal Consultation on Chagas Disease
in the Western Pacific (2011),” and issued the World
Health Assembling resolution of “WHA63.20 Chagas
disease: control and elimination (2010)". The general
aim is to control Chagas disease in non-endemic coun-
tries and contribute to global efforts to interrupting dis-
ease transmission by (i) preventing T. cruzi transmission
by systematically screening blood used for transfusions
and organs intended for transplantation; (ii) clinic diag-
nosis, case management, and treating patients, including
infected newborns through congenital transmission; and
(iii) sharing information about Chagas disease, and train-
ing health personnel to facilitate diagnosis and medical
care [48].
Second, a system for serological screening of blood or tis-
sue donors needs to be established. The United Kingdom
(UK) was the first country to implement the systematic
screening of at-risk blood donations for T. cruzi infection,
which has been carried out since 1999. Since then,
mandatory screening of blood donors at risk for T. cruzi in-
fection has been implemented in Spain (2005), Italy (2005),
France (2009), and Switzerland (2013) [48]. In the US,
widespread serological screening for blood donations has
been initiated, and now covers 75–90 % of blood donors,
but screening for T. cruzi has not been mandated and re-
mains voluntary [49]. In Sweden, Australia, and Portugal,
all individuals at risk for T. cruzi infection are excluded
from giving blood [48]. In other non-endemic countries, no
data has been determined on blood-donor screening until
now (see Table 2). However, in Europe, EU guidelines for
the quality and safety of blood, tissue, and cell donation are
currently being approved. Meanwhile, Italy, UK, Spain, and
France have applied measures to identify and detect at-risk
donors for organ, tissue, and cell transplantation [48]. In
the Netherlands, Chagas disease patients are excluded from
donating blood, or organs, tissues and cells for transplant-
ation [50]. In other non-endemic countries, screening of
solid organs and tissue is not yet implemented due to a lack
of correct techniques being developed. Globally, as part of
the systematic detection of congenital infections, there is
no legislation requiring the screening of pregnant women
for Chagas disease in place, except in some areas of Spain
(Catalonia, Galicia, and Valencia) and Italy (Tuscany) (see
Table 2). On the other hand, some nongovernmental pro-
grammes have being implemented in other regions of Spain
and Italy, as well as in Portugal, Switzerland, the US and
UK [48].
Third, a surveillance system for Chagas disease sup-
ported by prompt detection tests is urgently needed.
The surveillance system for Chagas disease has been
established at both the national and regional levels in
European countries with the coordination of the WHO.
However, biological diagnosis is not standardized in
terms of the choice of tests and algorithms, and no prac-
tical gold standard diagnostics are available. It is recom-
mended that commercial tests become available in non-
endemic regions. Frequently, the use of only one test
may be sufficient for screening blood donors, but the
WHO recommends using two different serological tests
for disease diagnosis. The main issue is to screen and
treat chronically infected non-pregnant women of child-
bearing age in order to prevent vertical transmission.
In general, all of non-endemic countries need to work
together to increase networking at the global level,
which focuses on strengthening global epidemiological
surveillance and the sharing of information; prevent
transmission by blood transfusions, organ transplant-
ation, and congenital transmission; and promote diag-
nostic tools for the management of diagnosed cases.
Research priorities for the control of American
trypanosomiasis
Given that more than 100 species of domestic and wild
mammals serve as reservoirs for the transmission of
Chagas disease, and a number of species of Triatominae
serve as potential vectors in nature, this has made the
control Chagas disease transmission very difficult.
Despite the remarkable progress made by the aforemen-
tioned control initiatives, key challenges still need to be
addressed.
Sustainability of control successes
Further efforts are required to maintain and consolidate
the achievements made in Chagas disease control,
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particularly in endemic areas where prevalence is at a
low level, and in non-endemic areas where Chagas dis-
ease is a new public health issue. Research priorities
must be diversified to simultaneously support the devel-
opment of multiple, alternative control strategies that
adapt to these new epidemiological scenarios. In endemic
countries, although experience from campaigns against
Triatominae throughout the Latin Americas should have
led to the main species of domestic populations being
interrupted, transmission data from some areas pertaining
to peridomestic and wild vectors, rather than domestic
ones, is still not available. It is in these areas where disease
emergence has been reported and may include local oral
outbreaks of food-borne Chagas disease. There have also
been reports on the emergence of some resistance foci to
pyrethroid insecticides of the main domestic vector, e.g.
T. infestans, as contributing to the ongoing active trans-
mission of Chagas disease in the Bolivian Chaco region in
spite of progress in vector control. In such a scenario,
vector monitoring is still a priority.
The development of innovative strategies to explore the
biological and behavioral traits of triatomine bugs and
paying more attention to new triatomine species is a way
to sustain the control programme. This is an important
approach for the control of Chagas disease transmission.
At the global level, there is a continual need to support
established community-based surveillance networks and
develop new community networks in disease emerging re-
gions. In order to sustain control efforts, information shar-
ing is of great importance. There needs to be a better
integration of knowledge and disciplines into disease pre-
vention and control programmes that goes beyond the
involvement of the academic sector, private industry, min-
istries of government, and local communities. The devel-
opment of a national database for epidemiological
surveillance of Chagas disease using geographical informa-
tion system (GIS) techniques has also been proposed [29].
The UNICEF/UNDP/World Bank/ WHO Special
Programme for Research and Training in Tropical Dis-
eases (TDR) has been working together with the WHO’s
information department to establish a global network for
a general health surveillance system for Chagas disease.
Like other vector-borne diseases, mandatory reporting of
all new cases of infection and all findings of domestic,
peridomestic, and silvatic populations of Triatominae is a
future goal [29].
Diagnostic tools
The diagnosis of Chagas disease is an important compo-
nent of national control programmes. Cure rates with
early treatment with benznidazole or nifurtimox in infants
is close to 100 % and 60–80 % in children under 15 years
old, but declines to nearly 0 % in the late chronic phase
of the disease [51–53]. It is reported that in Europe,
93.9–96.4 % of cases are underdiagnosed [45]. Therefore,
timely diagnosis is very important in order to increase the
cure rate. In general, diagnosis of acute infections is based
on parasite detection by parasitological studies of direct
visualization of T. cruzi, whereas diagnosis of chronic
American trypanosomiasis relies on serological methods.
Serological methods include indirect hemagglutination, in-
direct immunofluorescence antibody, and enzyme-linked
immunosorbent assay (ELISA). Up until now, 11 commer-
cialized T. cruzi infection rapid diagnostic tests have been
evaluated, with the SERODIA®-Chagas test, the Immuno-
Comb® II Chagas Ab Kit, and the SD Bioline Chagas Ab
Rapid test showing higher performance rates than the other
tests [52]. Molecular diagnostic assays have been developed
to detect low levels of kinetoplast DNA in the blood of T.
cruzi-infected individuals. Another scholar has evaluated
five serological methods and two molecular methods by
rapid diagnostic tests for Chagas disease and proposed that
the commercial Bioelisa Chagas® test showed the highest
sensitivity and specificity; the amplification of T. cruzi DNA
in blood samples showed low values of sensitivity, but high
values of specificity [54]. Rapid diagnosis of Chagas disease
is still a huge challenge because of the high incidence of in-
conclusive serological reactions and no sensitivity validation
for polymerase chain reaction (PCR). It is estimated that
the rate of underdiagnosis of Chagas disease in the world is
over 94 % [30]. Therefore, research on the diagnosis of
Chagas disease is still ongoing. Firstly, genome-wide screen-
ing and identification of new T. cruzi antigens is being con-
ducted [55]. Secondly, some new techniques have entered
clinical trials. These include real-time PCR, which has been
proven to be more sensitive and less time-consuming, and
may be used to identify highly infectious hosts and imple-
ment novel control strategies [56]. Thirdly, the Western
blot technique with excretory-secretory antigens of T. cruzi
epimastigotes has also shown to be effective in the
diagnosis of Chagas disease, and it has been reported
that this technique can be used as a confirmatory test
[57]. A proof-of-concept study of a Chagas urine nano-
particle test (Chunap) also showed good sensitivity to
capturing the antigen of T. cruzi from urine and was
useful for the early diagnosis of congenital Chagas dis-
ease [58]. Meanwhile, the applicability of detection
techniques in post-therapeutic monitoring of Chagas
disease is also essential to understanding the effective-
ness of treatment.
New drugs and treatment
Current treatment options for Chagas disease are limited
to only two drugs: benznidazole (Rochagan/LAFEPE and
Abarax/ELEA) and nifurtimox (LAMPIT/Bayer). Often,
these two drugs are effective in treating acute cases, but
show limited efficacy in chronically infected patients.
Most people infected with the T. cruzi parasite will not
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develop major clinical manifestations, and only a third
of these infections will develop into the chronic phase
[59]. Even in the acute stage, a high therapeutic failure
detected with differences in drug efficiency ranging from
0 to 100 % has been reported [11]. Treatment with ei-
ther benznidazole or nifurtimox can present a number
of clinical and therapeutic challenges, such as low effect-
ive for chronic phase, drug-resistance, etc. As a conse-
quence, there is an urgent need for new safe and
efficacious drug treatments that can be applicable both
in the acute and chronic phases of the disease. Efforts to
deliver new drug candidates for Chagas disease have
been very limited. A systematic literature review showed
that only naphthoquinones, diamidines, nitroimidazoles
and related compounds, and ruthenium complexes have
been studied in laboratory settings with failed results
due to toxicity or drug-ability issues [60–62]. Recently,
many institutions have joined the effort for the discovery
of treatment for Chagas disease due to the high-
throughput format of screening compounds and the
proof-of-concept investigations for identifying the chem-
ical molecular. A typical example of this is the oxaborole
series, which has shown potential to treat Chagas disease
[63, 64]. In the meantime, two candidate compounds for
anti-T. cruzi, namely posaconazole and ravuconazole,
have been entered into controlled proof-of-concept stud-
ies [65]. Unfortunately, the experimental outcome re-
ported a failure due to the long treatment duration
(60 days) and no superiority was shown to the old drug,
benznidazole. Despite the progress in the identification
of new drug candidates to treat Chagas disease, the
therapeutic proposal has remained the same for more
than 40 years, with no new drug for the treatment of
chronic Chagas disease being developed. Although there
is still, without a doubt, a knowledge gap, such as the
lack of translation between preclinical data and clinical
outcomes, drug discovery for Chagas disease is entering
a new and exciting era with the development of ad-
vanced technology and the drug screening platform [66].
The new data and acquired knowledge could encourage
a revision of the target product profile for Chagas
disease [66].
Coinfection and comorbidities
With the interruption of Chagas disease and rapid
urbanization, smaller numbers of new cases and acute
cases are being reported. Most cases of Chagas disease
are now in the chronic stage and frequently turn into a
life-long infection. Therefore, awareness on the number
of coinfections between mixed infections of different T.
cruzi genotypes and coinfection with HIV/AIDS has
been raised. For example, different pathologies of Chagas
disease are caused by six discrete typing units of T. cruzi
(TcI- TcVI) [67]. Variability of mixed genotypes of T.
cruzi congenital infection in Chile has been reported,
and TcII and TcV lineages of T. cruzi were the most fre-
quent in mixed infections [68]. Coinfection with Chagas
disease and HIV/AIDS has been reported widely in
Brazil, Argentina, and Colombia [68–72]. Out of a total
of nine million deaths recorded from 1999 to 2007 in
Brazil, coinfection with Chagas disease and HIV/AIDS
was mentioned in 74 cases [73]. Polyparasitism or coin-
fections are more often responsible for high morbidity
and mortality rates, and contribute to the higher degree
of variability of both disease progression and the success
of therapeutic interventions. Early diagnosis, therapy,
and monitoring are useful for avoiding reactivations and
improving late visceral involvement. For instance, Brazil
has established a network for attending to and studying
T. cruzi/HIV coinfection, and this will be extended to
form a Latin American network in the future [73]. Sci-
entists in Spain have provided guidelines for the diagno-
sis, treatment, and prevention of coinfections in areas
where Chagas disease is not endemic. Thorough under-
standing of the mechanism of polyparasitism and coin-
fections with Chagas disease is required to improve the
likelihood of diagnosis, treatment, prevention, and even-
tual elimination of Chagas disease [71, 74].
Conclusion
It has been demonstrated that the transmission of
American trypanosomiasis, commonly known as Chagas
disease, can be effectively interrupted by controlling the
main vectors in endemic areas, which has been imple-
mented in many Latin American countries. Other initia-
tives to control disease transmission have also been
implemented, with great success, to protect the approxi-
mately eight million people infected with T. cruzi in the
continent. However, more recently, Chagas disease has
become a global health issue as it has started spreading
to non-endemic countries. With globalization and cli-
mate change, much more attention has been paid to the
spreading of American trypanosomiasis at the global
level. More initiatives, such as serological screening of
blood donors and surveillance systems to respond to
imported cases of Chagas disease, have been established
in European and other non-endemic countries.
To prevent the introduction of the disease into non-
endemic countries, three main actions are needed: (i)
making more joint efforts at the global level to stop the
disease spreading, (ii) establishing a system for the sero-
logical screening of blood or tissue donors, and (iii)
forming a surveillance system for Chagas disease sup-
ported by prompt detection tests. In order to stop the
current global spreading of the disease, research prior-
ities should focus on the development of (i) innovative
strategies to sustain control successes, (ii) new and sen-
sitive diagnostic tools, (iii) new drugs and chemotherapy
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schemes, and (iv) determinants for measuring coinfec-
tion and comorbidities, as well as polyparasitism. These
activities will all support Chagas disease control and
elimination programmes.
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